| 规格: | 98% |
| 分子量: | 666.84 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
Background:
Niga-ichigoside F1, an orally active ursane triterpenoid, has antihyperlipidemic and antioxidant activities. Niga-ichigoside F1 can prevent high-fat diet (HFD)-induced hepatic steatosis[1].
Niga-ichigoside F1 (2.5, 5, 10, 20 μM; for 24 hours) inhibits lipid accumu-lation in free fatty acid (FFA)-treated HepG2 cells in a dose-dependent manner. Niga-ichigoside F1 has no effects on cell viability[1]. Both nuclear and cytoplasmic Nrf2 expressions are lowered in Con, Niga-ichigoside F1 (20 μM), FFA (1 mM), and Niga-ichigoside F1 plus FFA treated Nrf2-silenced cells[1].
Niga-ichigoside F1 (40 mg/kg; oral gavage; for 12 weeks) alleviates hepatic steatosis, possibly by significantly interacting with high-fat diet (HFD) to regulate lipid metabolism genes (including Srebp1c, Acc1, Fasn, Scd1, Cpt1a and Fabp5) in four-week-old male C57BL/6J mice[1].
[1]. Shu-Fang Xia, et al. Niga-ichigoside F1 ameliorates high-fat diet-induced hepatic steatosis in male mice by Nrf2 activation. Food Funct. 2018 Feb 21;9(2):906-916.
m.cnreagent.com